Factor concentrates for rare congenital coagulation disorders: where are we now?

Bibliography

• Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125:2052–2061.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104:1243–1252.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Duga S, Akhavan S, et al. Rare coagulation deficiencies. Haemophilia. 2002;8:308–321.
   PubMed Web of Science ®Google Scholar
• Shetty S, Shelar T, Mirgal D, et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia. 2014;20:575–581.
   PubMed Web of Science ®Google Scholar
• Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014;167:304–326.
   PubMed Web of Science ®Google Scholar
• Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman M, Beutler E, et al., editors. Williams hematology. 8th ed. New York (NY): McGraw-Hil; 2010. p. 1–33.
   Google Scholar
• de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–595.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost. 2013;39:579–584.
   PubMed Web of Science ®Google Scholar
• Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia. 2008;14:1151–1158.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10:615–621.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Menegatti M, Palla R, et al. Fibrinogen deficiency: preliminary results of the PRORBDD project. XXV Congress of the International Society on Thrombosis and Haemostasis; 2015; Toronto, Canada.
   Google Scholar
• Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107:204–206.
   PubMed Web of Science ®Google Scholar
• de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7–17.
   PubMed Web of Science ®Google Scholar
• Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385–392.
   PubMed Web of Science ®Google Scholar
• Remijn JA, Wu YP, Ijsseldijk MJ, et al. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost. 2001;85:736–742.
   PubMed Web of Science ®Google Scholar
• Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig. 1994;72:396–398.
   PubMedGoogle Scholar
• Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost. 2007;98:105–108.
   PubMed Web of Science ®Google Scholar
• Casini A, Neerman-Arbez M, Ariens RA, et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–919.
   PubMed Web of Science ®Google Scholar
• Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553–561.
   PubMed Web of Science ®Google Scholar
• Brennan SO, Chitlur M. Hypodysfibrinogenaemia and thrombosis in association with a new fibrinogen gamma chain with two mutations (gamma114Tyr–>His, and gamma320Asp deleted). Thromb Haemost. 2013;109:1180–1182.
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. 2010;115:2998–3007.
   PubMed Web of Science ®Google Scholar
• Asselta R, Robusto M, Braidotti P, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen gamma-module. J Thromb Haemost. 2015;13:1459–1467.
   PubMed Web of Science ®Google Scholar
• Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost. 2011;9:1687–1704.
   PubMed Web of Science ®Google Scholar
• Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130(Suppl 2):S7–S11.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Haertel S, Knaub S, et al. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4:1634–1637.
   PubMed Web of Science ®Google Scholar
• Rea C, Hunt BJ. Novel management of anticoagulant resistant thrombotic hypodysfibrinogenaemia. Thromb Res. 2012;130:785–787.
   PubMed Web of Science ®Google Scholar
• de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther. 2008;8:979–992.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol. 2009;7:788–790.
   PubMedGoogle Scholar
• Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res. 2009;124(Suppl 2):S9–S11.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009;7:2064–2069.
   PubMed Web of Science ®Google Scholar
• Negrier C, Rothschild C, Goudemand J, et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost. 2008;6:1494–1499.
   PubMed Web of Science ®Google Scholar
• Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32:247–253.
   PubMed Web of Science ®Google Scholar
• De Vries A, Rosenberg T, Kochwa S, et al. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med. 1961;30:486–494.
   PubMed Web of Science ®Google Scholar
• Kalina U, Stohr HA, Bickhard H, et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis. 2008;19:777–783.
   PubMed Web of Science ®Google Scholar
• Sartori MT, Milan M, de Bon E, et al. Thrombosis of abdominal aorta in congenital afibrinogenemia: case report and review of literature. Haemophilia. 2015;21:88–94.
   PubMed Web of Science ®Google Scholar
• Lebreton A, Casini A, Alhayek R, et al. Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis. Haemophilia. 2015;21:e108–e110.
   PubMed Web of Science ®Google Scholar
• Solomon C, Groner A, Ye J, et al. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost. 2015;113:759–771.
   PubMed Web of Science ®Google Scholar
• Schwartz BA, Rangarajan S, Peyvandi F, et al. Pharmacokinetic (PK) comparison of two fibrinogen concentrates for the treatment of congenital fibrinogen deficiency. 57th American Society of Haematology; 2014; Orlando, FL.
   Google Scholar
• Khayat C, El Khorassani M, Lambert T, et al. Pharmacokinetic and pharmacodynamic results of a multicenter, open-label, single arm study with a fibrinogen concentrate (FGTW) in subjects with afibrinogenemia. XXV Congress of the International Society on Thrombosis and Haemostasis; 2015; Toronto, Canada.
   Google Scholar
• Radulovic V, Baghaei F, Blixter IF, et al. Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery. J Thromb Haemost. 2012;10:1696–1698.
   PubMed Web of Science ®Google Scholar
• Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003;101:20–30.
   PubMed Web of Science ®Google Scholar
• Tracy PB, Eide LL, Bowie EJ, et al. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59–63.
   PubMed Web of Science ®Google Scholar
• Thalji N, Camire RM. Parahemophilia: new insights into factor v deficiency. Semin Thromb Hemost. 2013;39:607–612.
   PubMed Web of Science ®Google Scholar
• Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14:1164–1169.
   PubMed Web of Science ®Google Scholar
• Lak M, Sharifian R, Peyvandi F, et al. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol. 1998;103:1067–1069.
   PubMed Web of Science ®Google Scholar
• Delev D, Pavlova A, Heinz S, et al. Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency. Haemophilia. 2009;15:1143–1153.
   PubMed Web of Science ®Google Scholar
• Duckers C, Simioni P, Rosing J, et al. Advances in understanding the bleeding diathesis in factor V deficiency. Br J Haematol. 2009;146:17–26.
   PubMed Web of Science ®Google Scholar
• Lawrie AS, Berbenni C, Nardini I, et al. In vitro characterization of the first plasma-derived factor v concentrate in development. 60th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, SSC 2014; 2014; Milwaukee, WI.
   Google Scholar
• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–949.
   PubMed Web of Science ®Google Scholar
• Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost. 2009;35:400–406.
   PubMed Web of Science ®Google Scholar
• Mariani G, Herrmann FH, Bernardi F, et al. Clinical manifestations, management, and molecular genetics in congenital factor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7). Blood. 2000;96:374.
   PubMed Web of Science ®Google Scholar
• Mariani G, Dolce A, Batorova A, et al. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation – the surgical STER. Br J Haematol. 2011;152:340–346.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Dolce A, Mariani G, et al. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost. 2013;109:1051–1059.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013;98:538–544.
   PubMed Web of Science ®Google Scholar
• Mariani G, Napolitano M, Dolce A, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost. 2013;109:238–247.
   PubMed Web of Science ®Google Scholar
• van Geffen M, Mathijssen NC, Holme PA, et al. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thromb Res. 2013;132:116–122.
   PubMed Web of Science ®Google Scholar
• Mathijssen NC, Masereeuw R, Holme PA, et al. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res. 2013;132:256–262.
   PubMed Web of Science ®Google Scholar
• Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638–648.
   PubMed Web of Science ®Google Scholar
• Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26:385–391.
   PubMed Web of Science ®Google Scholar
• Berrettini M, Mariani G, Schiavoni M, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica. 2001;86:640–645.
   PubMed Web of Science ®Google Scholar
• Morfini M, Batorova A, Mariani G, et al. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost. 2014;112:424–425.
   PubMed Web of Science ®Google Scholar
• Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII – a critical appraisal. Haemophilia. 2006;12:19–27.
   PubMed Web of Science ®Google Scholar
• Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology. 2007;12:55–62.
   PubMed Web of Science ®Google Scholar
• Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131–136.
   PubMed Web of Science ®Google Scholar
• Moss J, Rosholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost. 2011;9:1368–1374.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Ehrenforth S, Karim FA, et al. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12:1244–1253.
   PubMed Web of Science ®Google Scholar
• Faranoush M, Abolghasemi H, Toogeh G, et al. A comparison between recombinant activated factor VII (Aryoseven) and novoseven in patients with congenital factor VII deficiency. Clin Appl Thromb Hemost. 2014. Epub 2014 Mar 19. DOI:10.1177/1076029614522545.
   Web of Science ®Google Scholar
• Zollner S, Schuermann D, Raquet E, et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost. 2014;12:220–228.
   PubMed Web of Science ®Google Scholar
• Frieling J, Stevens L, Reijers J, et al. Populationpharmacokinetic/pharmacodynamic modeling of a new recombinant human factor VIIA (LR769) to derive the dose to be studied in phase 3. XXV Congress of the International Society on Thrombosis and Haemostasis; 2015; Toronto, Canada.
   Google Scholar
• Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407–415.
   PubMed Web of Science ®Google Scholar
• Herrmann FH, Auerswald G, Ruiz-Saez A, et al. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia. 2006;12:479–489.
   PubMed Web of Science ®Google Scholar
• Girolami A, Randi ML, Ruzzon E, et al. Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors. Acta Haematol. 2006;115:58–63.
   PubMed Web of Science ®Google Scholar
• Nance D, Josephson NC, Paulyson-Nunez K, et al. Factor X deficiency and pregnancy: preconception counselling and therapeutic options. Haemophilia. 2012;18:e277–e285.
   PubMed Web of Science ®Google Scholar
• McMahon C, Smith J, Goonan C, et al. The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. Br J Haematol. 2002;119:789–791.
   PubMed Web of Science ®Google Scholar
• Karabel M, Soker M, Yildirim AT, et al. The clinical findings and prophylactic treatment in children with factor X deficiency. Pediatr Hematol Oncol. 2013;30:717–722.
   PubMed Web of Science ®Google Scholar
• Austin S, Norton M. Safety and efficacy of FACTOR X, a new high purity factor X concentrate: a phase III study in patients with hereditary factor X deficiency. Haemophilia. 2015;21:e260–e280.
   Web of Science ®Google Scholar
• Escobar M, Auerswald G, Austin S, et al. Experience of FACTOR X, a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery. Haemophilia. 2015;21:e260–e280.
   Web of Science ®Google Scholar
• Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39:621–631.
   PubMed Web of Science ®Google Scholar
• von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035–3042.
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood. 1995;85:429–432.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia. 2006;12:490–493.
   PubMed Web of Science ®Google Scholar
• Zucker M, Seligsohn U, Salomon O, et al. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost. 2014;12:1121–1130.
   PubMed Web of Science ®Google Scholar
• Rugeri L, Quelin F, Chatard B, et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia. 2010;16:771–777.
   PubMed Web of Science ®Google Scholar
• James P, Salomon O, Mikovic D, et al. Rare bleeding disorders – bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia. 2014;20(Suppl 4):71–75.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Wensley RT, Kernoff PB, et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost. 1992;67:314–319.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Goudemand J, Hemoleven Study G. United States’ factor XI-deficiency patients need a safer treatment. Am J Hematol. 2005;80:301–302.
   PubMed Web of Science ®Google Scholar
• Bauduer F, De Raucourt E, Boyer-Neumann C, et al. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia. 2015;21:481–489.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs P, Goudemand J, Hermans C, et al. FXI concentrate use and risk of thrombosis. Haemophilia. 2014;20:e349–e351.
   PubMed Web of Science ®Google Scholar
• Pike GN, Bolton-Maggs PH. Factor XI-related thrombosis and the role of concentrate treatment in factor XI deficiency. Haemophilia. 2015;21:477–480.
   PubMed Web of Science ®Google Scholar
• Dash CH, Gascoigne EW, Gillanders KR. Further clinical experience with a factor XI concentrate. 22nd Congress of the International Society of Thrombosis and Haemostasis; 2009; Boston, MA.
   Google Scholar
• Boehlen F, Casini A, Pugin F, et al. Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery. Blood Coagul Fibrinolysis. 2013;24:347–350.
   PubMed Web of Science ®Google Scholar
• Batty P, Honke A, Bowles L, et al. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia. 2015;21:490–495.
   PubMed Web of Science ®Google Scholar
• Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101:4783–4788.
   PubMed Web of Science ®Google Scholar
• Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost. 2013;39:632–641.
   PubMed Web of Science ®Google Scholar
• Muszbek L, Ariens RA, Ichinose A, et al. Factor XIII: recommended terms and abbreviations. J Thromb Haemost. 2007;5:181–183.
   PubMed Web of Science ®Google Scholar
• Ariens RA, Lai TS, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743–754.
   PubMed Web of Science ®Google Scholar
• Kohler HP, Ichinose A, Seitz R, et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9:1404–1406.
   PubMed Web of Science ®Google Scholar
• Anwar R, Minford A, Gallivan L, et al. Delayed umbilical bleeding–a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics. 2002;109:E32.
   PubMed Web of Science ®Google Scholar
• Karimi M, Bereczky Z, Cohan N, et al. Factor XIII deficiency. Semin Thromb Hemost. 2009;35:426–438.
   PubMed Web of Science ®Google Scholar
• Lak M, Peyvandi F, Ali Sharifian A, et al. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost. 2003;1:1852–1853.
   PubMed Web of Science ®Google Scholar
• Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost. 2006;4:19–25.
   PubMed Web of Science ®Google Scholar
• Pike GN, Bolton-Maggs PH. Factor deficiencies in pregnancy. Hematol Oncol Clin North Am. 2011;25:359–378, viii–ix.
   PubMed Web of Science ®Google Scholar
• Lusher J, Pipe SW, Alexander S, et al. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia. 2010;16:316–321.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Palla R, Menegatti M, et al. Factor XIII deficiency: preliminary results of the PRORBDD project. XXV Congress of the International Society on Thrombosis and Haemostasis; 2015; Toronto, Canada.
   Google Scholar
• Nugent D. Corifact/Fibrogammin(R) P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res. 2012;130(Suppl 2):S12–S14.
   PubMed Web of Science ®Google Scholar
• Ashley C, Chang E, Davis J, et al. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015;21:102–108.
   PubMed Web of Science ®Google Scholar
• Nugent DJ, Ashley C, Garcia-Talavera J, et al. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015;21:95–101.
   PubMed Web of Science ®Google Scholar
• Kerlin B, Brand B, Inbal A, et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J Thromb Haemost. 2014;12:2038–2043.
   PubMed Web of Science ®Google Scholar
• Reynolds TC, Butine MD, Visich JE, et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost. 2005;3:922–928.
   PubMed Web of Science ®Google Scholar
• Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006;108:57–62.
   PubMed Web of Science ®Google Scholar
• Inbal A, Oldenburg J, Carcao M, et al. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012;119:5111–5117.
   PubMed Web of Science ®Google Scholar
• Williams M, Will A, Stenmo C, et al. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients. Haemophilia. 2014;20:99–105.
   PubMed Web of Science ®Google Scholar
• Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J. 2015;13:4.
   PubMedGoogle Scholar
• Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser. 2014;9:30–36.
   PubMedGoogle Scholar
• El-Ekiaby M, Goubran HA, Radosevich M, et al. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. Haemophilia. 2011;17:e884–e888.
   PubMed Web of Science ®Google Scholar
• El-Ekiaby M, Sayed MA, Caron C, et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010;20:48–61.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost. 2013;11(Suppl 1):84–98.
   PubMed Web of Science ®Google Scholar
• Shetty S, Ghosh K. Novel therapeutic approaches for haemophilia. Haemophilia. 2015;21:152–161.
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–497.
   PubMed Web of Science ®Google Scholar
• Nuzzo F, Radu C, Baralle M, et al. Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation. Blood. 2013;122:3825–3831.
   PubMed Web of Science ®Google Scholar